BDTX

Black Diamond Therapeutics, Inc. is a leading biotechnology company based in Cambridge, Massachusetts, focused on pioneering tumor-agnostic therapies through its proprietary platform that embodies precision medicine. By targeting distinct oncogenic drivers, Black Diamond aims to address urgent patient needs in genetically defined cancers, underscoring its commitment to enhancing therapeutic options in oncology. The company is advancing a robust pipeline of promising candidates through clinical trials, solidifying its position as an innovator in transformative cancer therapies with the potential to significantly improve patient outcomes.